160 related articles for article (PubMed ID: 38158572)
1. Venous Thromboembolism in Exploration Class Human Spaceflight.
Levasseur S; Purvis N; Trozzo S; Chung SH; Ades M; Drudi LM
Aerosp Med Hum Perform; 2024 Jan; 95(1):45-53. PubMed ID: 38158572
[No Abstract] [Full Text] [Related]
2. The effect of microgravity on the human venous system and blood coagulation: a systematic review.
Kim DS; Vaquer S; Mazzolai L; Roberts LN; Pavela J; Watanabe M; Weerts G; Green DA
Exp Physiol; 2021 May; 106(5):1149-1158. PubMed ID: 33704837
[TBL] [Abstract][Full Text] [Related]
3. Potential Venous Thromboembolism Risk in Female Astronauts.
Jain V; Ploutz-Snyder R; Young M; Charvat JM; Wotring VE
Aerosp Med Hum Perform; 2020 May; 91(5):432-439. PubMed ID: 32327017
[No Abstract] [Full Text] [Related]
4. Albumin, oral contraceptives, and venous thromboembolism risk in astronauts.
Zwart SR; Auñón-Chancellor SM; Heer M; Melin MM; Smith SM
J Appl Physiol (1985); 2022 May; 132(5):1232-1239. PubMed ID: 35389755
[TBL] [Abstract][Full Text] [Related]
5. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
6. Superficial venous disease and combined hormonal contraceptives: a systematic review.
Tepper NK; Marchbanks PA; Curtis KM
Contraception; 2016 Sep; 94(3):275-9. PubMed ID: 25835269
[TBL] [Abstract][Full Text] [Related]
7. The thrombotic risk of spaceflight: has a serious problem been overlooked for more than half of a century?
Limper U; Tank J; Ahnert T; Maegele M; Grottke O; Hein M; Jordan J
Eur Heart J; 2021 Jan; 42(1):97-100. PubMed ID: 32428936
[TBL] [Abstract][Full Text] [Related]
8. SOGC clinical practice guideline. No. 252, December 2010. Oral contraceptives and the risk of venous thromboembolism: an update.
Reid R;
J Obstet Gynaecol Can; 2010 Dec; 32(12):1192-1197. PubMed ID: 21176332
[TBL] [Abstract][Full Text] [Related]
9. Search for Venous Endothelial Biomarkers Heralding Venous Thromboembolism in Space: A Qualitative Systematic Review of Terrestrial Studies.
Harris K; Laws JM; Elias A; Green DA; Goswami N; Jordan J; Kamine TH; Mazzolai L; Petersen LG; Winnard AJ; Weber T
Front Physiol; 2022; 13():885183. PubMed ID: 35574486
[No Abstract] [Full Text] [Related]
10. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden.
Rintelen C; Mannhalter C; Ireland H; Lane DA; Knöbl P; Lechner K; Pabinger I
Br J Haematol; 1996 May; 93(2):487-90. PubMed ID: 8639453
[TBL] [Abstract][Full Text] [Related]
11. First-time use of newer oral contraceptives and the risk of venous thromboembolism.
Suissa S; Blais L; Spitzer WO; Cusson J; Lewis M; Heinemann L
Contraception; 1997 Sep; 56(3):141-6. PubMed ID: 9347203
[TBL] [Abstract][Full Text] [Related]
12. Smoking and use of oral contraceptives: impact on thrombotic diseases.
Lidegaard O
Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S357-63. PubMed ID: 10368521
[TBL] [Abstract][Full Text] [Related]
13. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties.
Koster T; Small RA; Rosendaal FR; Helmerhorst FM
J Intern Med; 1995 Jul; 238(1):31-7. PubMed ID: 7608644
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism in young female while on oral contraceptives: high frequency of inherited thrombophilia and analysis of thrombotic events in 400 czech women.
Dulícek P; Malý J; Pecka M; Beránek M; Cermáková E; Malý R
Clin Appl Thromb Hemost; 2009 Oct; 15(5):567-73. PubMed ID: 19117968
[TBL] [Abstract][Full Text] [Related]
15. SOGC clinical practice guidelines: Oral contraceptives and the risk of venous thromboembolism: an update: no. 252, December 2010.
Reid R; Leyland N; Wolfman W; Allaire C; Awadalla A; Best C; Dunn S; Lemyre M; Marcoux V; Menard C; Potestio F; Rittenberg D; Singh S; Senikas V;
Int J Gynaecol Obstet; 2011 Mar; 112(3):252-6. PubMed ID: 21416656
[TBL] [Abstract][Full Text] [Related]
16. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
Price DT; Ridker PM
Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptives and thrombotic disease: risk of venous thromboembolism.
Helmerhorst FM; Bloemenkamp KW; Rosendaal FR; Vandenbroucke JP
Thromb Haemost; 1997 Jul; 78(1):327-33. PubMed ID: 9198174
[TBL] [Abstract][Full Text] [Related]
18. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.
Dinger J; Assmann A; Möhner S; Minh TD
J Fam Plann Reprod Health Care; 2010 Jul; 36(3):123-9. PubMed ID: 20659364
[TBL] [Abstract][Full Text] [Related]
19. Gynecologic Risk Mitigation Considerations for Long-Duration Spaceflight.
Steller JG; Blue RS; Burns R; Bayuse TM; Antonsen EL; Jain V; Blackwell MM; Jennings RT
Aerosp Med Hum Perform; 2020 Jul; 91(7):543-564. PubMed ID: 32591031
[No Abstract] [Full Text] [Related]
20. Hormonal contraceptives and venous thromboembolism: an epidemiological update.
Plu-Bureau G; Maitrot-Mantelet L; Hugon-Rodin J; Canonico M
Best Pract Res Clin Endocrinol Metab; 2013 Feb; 27(1):25-34. PubMed ID: 23384743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
